Boston Scientific has initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The July 11 enforcement reports detail issues across more than 80,000 units per SKU, with worldwide distribution that could pressure margins and brand trust in the company's endoscopy segment. While the financial impact remains unclear, the recalls highlight manufacturing and regulatory risks as Boston Scientific integrates recent acquisitions and scales globally. The company's investment narrative projects $25.8 billion in revenue and $4.8 billion in earnings by 2029, requiring 7.8% annual revenue growth and a $1.2 billion earnings increase from the current $3.6 billion. The most pessimistic analysts already forecast slower 6.9% annual revenue growth and $4.5 billion in earnings, and these recalls may reinforce concerns about quality control and integration risk.
Boston Scientific CorpVoluntary Class II recalls for sterile-packaging breaches raise regulatory and quality control risks.